Edgewise Therapeutics, Inc. Accumulated Other Comprehensive Income
Edgewise Therapeutics, Inc. (EWTX) had Accumulated Other Comprehensive Income of -$500.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-06
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$500.00K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$252.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $677.00K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $701.00K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | -$500.00K 10-Q · filed 2026-08-06 |
| 2026-03-31 | -$252.00K 10-Q · filed 2026-05-07 |
| 2025-12-31 | $677.00K 10-Q · filed 2026-08-06 |
| 2025-09-30 | $701.00K 10-Q · filed 2025-11-06 |
| 2025-06-30 | $204.00K 10-Q · filed 2025-08-07 |
| 2025-03-31 | $401.00K 10-Q · filed 2025-05-08 |
| 2024-12-31 | $420.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.05M 10-Q · filed 2024-11-07 |
| 2024-06-30 | -$1.05M 10-Q · filed 2024-08-08 |
| 2024-03-31 | -$861.00K 10-Q · filed 2024-05-09 |
| 2023-12-31 | $99.00K 10-K · filed 2025-03-03 |
| 2023-09-30 | -$424.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | -$547.00K 10-Q · filed 2023-08-10 |
| 2023-03-31 | -$251.00K 10-Q · filed 2023-05-11 |
| 2022-12-31 | -$1.35M 10-K · filed 2024-02-22 |
| 2022-09-30 | -$2.18M 10-Q · filed 2022-11-03 |
| 2022-06-30 | -$2.34M 10-Q · filed 2022-08-04 |
| 2022-03-31 | -$1.93M 10-Q · filed 2022-05-11 |
| 2021-12-31 | -$514.00K 10-K · filed 2023-02-23 |
| 2021-09-30 | -$24.00K 10-Q · filed 2021-11-10 |
| 2021-06-30 | -$33.00K 10-Q · filed 2021-08-09 |
| 2021-03-31 | -$54.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |